Baltimore Innovation Week 2017

John W. Davis, II, founded Notice and Comment (N&C) in January 2013. He is the former Director of Major Crimes Division and Chief Homicide Prosecutor for the U.S. Department of Justice in the U.S. Virgin Islands, during the Clinton administration. Following his several years of public service, John practiced as a criminal defense attorney, debate coach, and professor of ethics and communications law at George Mason University, Howard University, and Towson University.

John has served as a consultant to numerous federal agencies through Debate Solutions Inc., a Washington, DC-based frm he launched to organize debates between student teams from leading national universities. These venues focused on actual policy issues of the day, eliciting unique insights for regulators as they considered specific rules.

Prior to his policy debate work, John served as Vice President with Northern Trust, based in Chicago, where he spearheaded the bank’s program to attract high-net-worth clients. Until recently he served as chairman of the board of directors of Sharp Dressed Man, a nonproft organization based in Baltimore, dedicated to providing professional clothing to disadvantaged men who are seeking employment.

Michelle Menard is an award wining game designer, published author (Game Development with Unity), and 10-year veteran of the industry. She has previously worked in both the mobile and AAA market, and as a consultant under Artemic Games, LLC, partnering with other companies to provide core system design, itemization, auditing, and documentation. Once she was invited to the White House to blabber about game design and crowd-sourcing for big data. Michelle is currently the lead designer at Oxide Games, and is also a co-founder of Fishwizard Games, a small boardgame company exploring strategy games set in the Gateway universe. Gateway: Uprising, their first title, is due out in stores Q3 of this year.

Michelle also serves as an adjunct professor at UMBC and SCAD, teaching game design, theory, and game history, and has taught intro C# game development courses for the local non-profit Code in the Schools. She holds a double BA in Applied Mathematics and Music Theory from Brown University, and an MFA in Game and Interactive Design from SCAD.

Brad Hennessie is the CEO of NextStep Robotic Inc., a company whose portable robotic ankle exoskeleton is being developed as the first ever treatment option to reverse foot drop in stroke victims. Foot drop, which occurs in a wide range of neurological and orthopedic conditions, is recognized as the inability to lift the toe during normal walking. He has been working with the inventors of this technology for 8 years, managing multiple grants with Drs. Macko, Roy, and Forrester. He started with the team as a single study coordinator and quickly grew into a leadership role over the past few years, helping manage the day-to-day tasks and long term goals for the Maryland Exercise and Robotics Center of Excellence (MERCE). MERCE is a ~$7M/year research organization originally founded by Dr. Richard Macko that is part of the Baltimore VA Medical Center and the Department of Neurology at the University of Maryland School of Medicine. Brad’s conception of the business model and commercialization plan led to the team’s successful TEDCO MII Phase I/II submission and attracting their first external investor.

Since transitioning out of the robotics lab and starting full time with NextStep Robotics, he has directed an engineering team with Dr. Gil Blankenship at the Maryland Development Center to create the first prototype of the portable ankle robot.

Brad’s early development as a leader was shaped by his 8 years in the Maryland Army National Guard where he learned the importance of having confidence in the quality of a product by being a parachute rigger.

Aaron is a radio and podcast producer at WYPR. His current project with Wendel Partrick is called Out of the Blocks. It is an immersive podcast that blends voices and sounds from the streets of Baltimore. A tapestry of stories hidden in plain sight, with an original musical score.

Dr. Jennifer Reynolds is an experienced and entrepreneurial executive with more than twenty years of experience growing companies in start - up/early stage biotechnology and high technology environments. She is currently overseeing the University of Maryland, Baltimore County’s 60+ company incubation/acceleration program in life sciences, cybersecurity and clean technology and has a deep passion and interest in advancing the commercialization of new technologies within diverse high-technology sectors. Previously, she served in a COO capacity at a molecular diagnostics platform company in MD, growing the company from the ground up. She has also served as a DNA Forensics Expert and Crime Laboratory Director at one of the nation’s most prestigious private forensics testing laboratories. Jennifer has a B.S. degree in Biology from Virginia Tech, a PhD in Human Genetics from the Medical College of Virginia (VCU), and an MBA degree from the Executive MBA program at Robert H. Smith School of Business, University of Maryland College Park.

Dr. Abigail McElhinny joined Personal Genome Diagnostics as Senior Vice President, Research & Development and Operations in May 2016 from Ventana Medical Systems (Roche Tissue Diagnostics), where she held a number of different roles of increasing responsibilities. At Ventana, Abigail held the position as Vice President of Assay and Reagent Development where she built and led Research & Development teams with the goal of developing new assays for the BenchMark and next generation platforms. Dr. McElhinny represented Ventana on the pivotal PD-L1 Blueprint initiative, and successfully oversaw key scientific projects critical to the business, while her organization doubled in size. Abigail previously served as Senior Project Leader for CDx lifecycle projects, working with regulatory, clinical affairs, quality, and biostatistics teams to build the necessary processes and requirements to support pharma clinical trials and obtain FDA approval for CDx assays, including Ventana’s ALK (D5F3) CDx IHC assay and HER2 Dual ISH assays. Abigail received her Ph.D. from Northeastern University in Immunology and Biochemistry, and completed a post-doctoral fellowship at University of Arizona in Cell Biology, focused on molecular mechanisms of cardiac muscle development, cardiomyopathies and muscle remodeling.

Emily P. English is the Chief Product Officer and Interim President of Gemstone Biotherapeutics, LLC. In this role, she will lead Gemstone’s product development plans to bring innovative wound healing technologies from the lab bench into the clinic. She thrives on for working with small teams at the leading edge of technology development, and she brings a passion shaped by personal experience to the development of wound healing solutions. Prior to joining Gemstone, Dr. English spent eight years at the Johns Hopkins University Applied Physics Laboratory, where she was the Global Communications Program Manager. She holds a Bachelor’s degree, Magna cum laude, in chemistry from the University of Maryland, College Park, and a Ph.D. in chemistry from the University of Wisconsin, Madison. Outside of work, Dr. English enjoys spending time with her family, and she is an avid curler.

Natalie D. Eddington, PhD, FAAPS, FCP, is dean of the University of Maryland School of Pharmacy (UMSOP) and a professor of pharmaceutical sciences. She is also executive director of University Regional Partnerships for the University of Maryland, Baltimore (UMB).

Dr. Eddington is a nationally known expert in drug delivery and pharmacokinetics. Her research focuses on various medications used in the treatment of cancer, epilepsy, arthritis, and drugs of abuse and on understanding the role of biopharmaceutics and pharmacokinetics in elucidating the underlying mechanisms important in optimizing drug therapy. 

Under Dr. Eddington’s leadership, the School of Pharmacy has established a number of centers and programs including the FDA-supported Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), which is a collaborative agreement with the FDA to promote innovation in support of the development and evaluation of safe and effective products. Dr. Eddington has designed numerous international regulatory courses for clinicians and scientists from South Korea, Argentina, Brazil, the United States, and Japan on the United States’ drug development process and the FDA regulatory infrastructure surrounding medication and device development. Most recently, under Dr. Eddington’s leadership, the School has launched a transformational pharmapreneurism initiative, which seeks to position the School’s world class faculty, its wonderful students, and exceptional staff to achieve their career aspirations and address our nation’s health care, research, policy, and societal needs.